Suppr超能文献

[用于血液系统恶性肿瘤的口服抗肿瘤药物]

[Oral antitumor drugs for hematological malignancies].

作者信息

Ohnishi K

机构信息

Dept. of Internal Medicine III, Hamamatsu University School of Medicine.

出版信息

Gan To Kagaku Ryoho. 1999 Feb;26(3):295-300.

Abstract

The oral antitumor drugs against hematological malignancies are summarized. Sobuzoxane, a topoisomerase II inhibitor, is useful for the treatment of lymphoma, especially adult T cell leukemia/lymphoma. Sobuzoxane has an effect to protect against doxorubicin cardiotoxicity. Cytarabine ocfosfate, a derivative of cytosine arabinoside, is a useful agent against acute leukemia and MDS, especially RAEB, RAEB in T, CMMoL. The JALSG AML 92 study for APL with all-trans retinoic acid resulted in a 89% CR rate in 196 and 64% 4-year DFS in CR cases. Hydroxycarbamide is can control the WBC in CML. This agent is also effective for other myeloproliferative disorders, such as acute leukemia and MDS. Oral administration of 50 mg etoposide daily showed a good outcome in old patients with malignant lymphoma. For old patients and those with refractory hematological malignancies, oral administration of these agents can offer a new form of palliative therapy to allow them to remain at home while maintaining a high quality of life.

摘要

总结了用于治疗血液系统恶性肿瘤的口服抗肿瘤药物。拓扑异构酶II抑制剂索布佐生对淋巴瘤尤其是成人T细胞白血病/淋巴瘤的治疗有用。索布佐生具有预防多柔比星心脏毒性的作用。阿糖胞苷磷酸酯,一种阿糖胞苷的衍生物,是治疗急性白血病和骨髓增生异常综合征(尤其是难治性贫血伴原始细胞过多、转化型难治性贫血伴原始细胞过多、慢性粒-单核细胞白血病)的有效药物。日本成人白血病研究组(JALSG)针对急性早幼粒细胞白血病采用全反式维甲酸的AML 92研究中,196例患者的完全缓解率为89%,完全缓解病例的4年无病生存率为64%。羟基脲可控制慢性粒细胞白血病的白细胞。该药物对其他骨髓增殖性疾病如急性白血病和骨髓增生异常综合征也有效。每天口服50毫克依托泊苷对老年恶性淋巴瘤患者显示出良好疗效。对于老年患者和难治性血液系统恶性肿瘤患者,口服这些药物可提供一种新的姑息治疗形式,使他们能够居家并维持较高的生活质量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验